This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n3http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F10%3A8258%21RIV11-MZ0-00064165/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F10%3A8258%21RIV11-MZ0-00064165
rdf:type
n3:Vysledek skos:Concept
dcterms:description
Annotation: Summary - The CONFIRM trial has shown a statistically significant increase in TTP for F500 compared with F250 in postemenopausal women, without increase in toxicity. Annotation: Summary - The CONFIRM trial has shown a statistically significant increase in TTP for F500 compared with F250 in postemenopausal women, without increase in toxicity.
dcterms:title
Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer
skos:prefLabel
Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer
skos:notation
RIV/00064165:_____/10:8258!RIV11-MZ0-00064165
n5:aktivita
n9:V
n5:aktivity
V
n5:cisloPeriodika
30
n5:dodaniDat
n14:2011
n5:domaciTvurceVysledku
n13:5081513
n5:druhVysledku
n15:J
n5:duvernostUdaju
n10:S
n5:entitaPredkladatele
n16:predkladatel
n5:idSjednocenehoVysledku
285079
n5:idVysledku
RIV/00064165:_____/10:8258
n5:jazykVysledku
n12:eng
n5:klicovaSlova
Breast cancer; postmenopausal women; fulvestrant; estrogen; CONFIRM trial
n5:klicoveSlovo
n8:postmenopausal%20women n8:fulvestrant n8:CONFIRM%20trial n8:estrogen n8:Breast%20cancer
n5:kodStatuVydavatele
US - Spojené státy americké
n5:kontrolniKodProRIV
[B698155702A6]
n5:nazevZdroje
Journal of Clinical Oncology
n5:obor
n7:FD
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
15
n5:rokUplatneniVysledku
n14:2010
n5:svazekPeriodika
28
n5:tvurceVysledku
Pendergrass, Kelly Sapunar, Francisco Bondarenko, Igor, N. Garnett, Sally Petruželka, Luboš Khasanov, Rustem Lichinitser, Mikhail, R. Pedrini, Jose, L. Martin, Miguel Torres, Roberto Verhoeven, Didier Jerusalem, Guy Smirnova, Iya Di Leo, Angelo Lindemann, Justin, P. O.
n5:wos
000283056400027
s:issn
0732-183X
s:numberOfPages
7